IL-6 concentrations declined significantly in MASLD patients by 821 pg/mL (95% CI 128–1514), compared to a 729 pg/mL reduction in non-MASLD patients (95% CI 35–1422), reflecting early attenuation of systemic inflammation. The gene discussed is IL6; the disease is metabolic dysfunction-associated steatotic liver disease.